

Ubrolexin intramammary suspension for lactating dairy COWS

Authorised

- Cefalexin monohydrate
- KANAMYCIN MONOSULPHATE

Product identification

Medicine name:

Ubrolexin intramammary suspension for lactating dairy cows

Active substance:

Cefalexin monohydrate

KANAMYCIN MONOSULPHATE

Target species:

Cattle

Route of administration:

Intramammary use

Product details

Active substance and strength:

Cefalexin monohydrate

210.36 milligram(s) / 1.00 Syringe

KANAMYCIN MONOSULPHATE

120247.00 international unit(s) / 1.00 Syringe

Pharmaceutical form:

Intramammary suspension

Withdrawal period by route of administration:

Intramammary use:

-

Cattle

- Meat and offal. 10 day
 - Milk. 5 day
-

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ51RD01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Germany

Available in:

Germany

Package description:

Cardboard box with 20 single use intramammary syringes and 20 teat wipes (containing isopropanol 70%). Each 10 g syringe contains 12 ml intramammary suspension and consists of a barrel with plunger and sealed sterile tip, all made of low density polyethylene.

Cardboard box with 10 single use intramammary syringes and 10 teat wipes (containing isopropanol 70%). Each 10 g syringe contains 12 ml intramammary suspension and consists of a barrel with plunger and sealed sterile tip, all made of low density polyethylene.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Well-established use application (Article 13a of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:

1/08/2008

Manufacturing sites for batch release:

Univet Limited

Responsible authority:

Federal Office Of Consumer Protection And Food Safety

Authorisation number:

401157.00.00

Date of authorisation status change:

22/11/2012

Reference member state:

Ireland

Procedure number:

IE/V/0221/001

Concerned member states:

Austria Belgium Cyprus Czechia Estonia France Germany Greece Hungary
Italy Latvia Lithuania Luxembourg Netherlands Poland Portugal Romania
Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents

English (PDF)

Published on: 28/09/2025

[Download](#)